For brevity, “Died” corresponds to poor outcome as defined in the “Methods” section. VF/VT indicates ventricular fibrillation/ventricular tachycardia; DC, direct current; ROSC, return of spontaneous circulation.aWithin 4 hours of ROSC, 15 patients in the control group and 23 patients in the vasopressin-steroids-epinephrine (VSE) group experienced vasopressor-unresponsive hypotension (ie, treatment-refractory shock) and died.bIn the control group, all 3 patients were alive on days 1 and 10, and 1 patient was alive at hospital discharge with a Cerebral Performance Category (CPC) score of 1 or 2. In the VSE group, all 10 patients were alive on day 1, 6 patients were alive on day 10, and 2 patients were alive at hospital discharge with a CPC score of 1 or 2.cThirteen patients of the VSE group also received open-label hydrocortisone.dThis was done according to attending physician decision. According to the study protocol, control patients should receive saline placebo and VSE patients hydrocortisone; on day 10 placebo or hydrocortisone should be discontinued in both groups.eIn the control group, 6 survivors originated from the postresuscitation shock subgroup; in the VSE group, 16 survivors originated from the postresuscitation shock subgroup.fIn post hoc analysis (see also the online Supplement), 5 controls and 11 VSE patients achieved 1-year survival with a CPC score of 1 or 2.
Probability of survival with a Cerebral Performance Category (CPC) score of 1 or 2 to day 60 after randomization, which was identical to survival to hospital discharge with a CPC score of 1 or 2, in all 268 patients (A) and in the 149 patients with postresuscitation shock (B). The numbers of patients at risk were reduced according to the time points of occurrence of patient death or the earliest follow-up neurological evaluation that was consistent with a subsequent, poor neurological outcome (ie, CPC score of ≥3) that was ultimately confirmed at the final neurological evaluation at hospital discharge. VSE indicates vasopressin-steroids-epinephrine.
eMethods. Additional Features of Study Methodology and Statistical Analysis.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, Steroids, and Epinephrine and Neurologically Favorable Survival After In-Hospital Cardiac ArrestA Randomized Clinical Trial. JAMA. 2013;310(3):270–279. doi:10.1001/jama.2013.7832
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Among patients with cardiac arrest, preliminary data have shown improved return of spontaneous circulation and survival to hospital discharge with the vasopressin-steroids-epinephrine (VSE) combination.
To determine whether combined vasopressin-epinephrine during cardiopulmonary resuscitation (CPR) and corticosteroid supplementation during and after CPR improve survival to hospital discharge with a Cerebral Performance Category (CPC) score of 1 or 2 in vasopressor-requiring, in-hospital cardiac arrest.
Design, Setting, and Participants
Randomized, double-blind, placebo-controlled, parallel-group trial performed from September 1, 2008, to October 1, 2010, in 3 Greek tertiary care centers (2400 beds) with 268 consecutive patients with cardiac arrest requiring epinephrine according to resuscitation guidelines (from 364 patients assessed for eligibility).
Patients received either vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (VSE group, n = 130) or saline placebo plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (control group, n = 138) for the first 5 CPR cycles after randomization, followed by additional epinephrine if needed. During the first CPR cycle after randomization, patients in the VSE group received methylprednisolone (40 mg) and patients in the control group received saline placebo. Shock after resuscitation was treated with stress-dose hydrocortisone (300 mg daily for 7 days maximum and gradual taper) (VSE group, n = 76) or saline placebo (control group, n = 73).
Main Outcomes and Measures
Return of spontaneous circulation (ROSC) for 20 minutes or longer and survival to hospital discharge with a CPC score of 1 or 2.
Follow-up was completed in all resuscitated patients. Patients in the VSE group vs patients in the control group had higher probability for ROSC of 20 minutes or longer (109/130 [83.9%] vs 91/138 [65.9%]; odds ratio [OR], 2.98; 95% CI, 1.39-6.40; P = .005) and survival to hospital discharge with CPC score of 1 or 2 (18/130 [13.9%] vs 7/138 [5.1%]; OR, 3.28; 95% CI, 1.17-9.20; P = .02). Patients in the VSE group with postresuscitation shock vs corresponding patients in the control group had higher probability for survival to hospital discharge with CPC scores of 1 or 2 (16/76 [21.1%] vs 6/73 [8.2%]; OR, 3.74; 95% CI, 1.20-11.62; P = .02), improved hemodynamics and central venous oxygen saturation, and less organ dysfunction. Adverse event rates were similar in the 2 groups.
Conclusion and Relevance
Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status.
clinicaltrials.gov Identifier: NCT00729794
Neurological outcome after cardiac arrest has been the main end point of several randomized clinical trials (RCTs).1-4 Neurologically favorable survival differs from overall survival. Among cardiac arrest survivors, the prevalence of severe cerebral disability or vegetative state ranges from 25% to 50%.2-6
In a previous single-center RCT,7 combined vasopressin-epinephrine during cardiopulmonary resuscitation (CPR) and corticosteroid supplementation during and after CPR vs epinephrine alone during CPR and no steroids resulted in improved overall survival to hospital discharge. Patients in the vasopressin-steroids-epinephrine (VSE) group had more frequent return of spontaneous circulation (ROSC) and attenuated postresuscitation systemic inflammatory response7,8 and organ dysfunction.7 However, this preliminary study could not reliably assess VSE efficacy with respect to neurologically favorable survival to hospital discharge. We addressed this question with a 3-center RCT of vasopressor-requiring, in-hospital cardiac arrest.
We conducted the study in the intensive and coronary care units (ICUs/CCUs), emergency departments, general wards, and operating rooms of 2 tertiary care centers in Athens, Greece (Evaggelismos General Hospital and 401 Greek Army Hospital) and 1 tertiary care center in Larissa, Greece (Larissa University Hospital). The study-protocol has been detailed elsewhere.7 (For center-endorsed, general ICU therapeutic strategies, refer to the Supplement.)
Eligible patients had experienced in-hospital, vasopressor-requiring cardiac arrest according to guidelines for resuscitation from 2005.9 Exclusion criteria were age younger than 18 years, terminal illness (ie, life expectancy <6 weeks) or do-not-resuscitate status, cardiac arrest due to exsanguination (eg, ruptured aortic aneurysm), cardiac arrest before hospital admission, treatment with intravenous corticosteroids before arrest, and previous enrollment in or exclusion from the current study.
Consent was not obtained for the CPR drug combination, which was based on standard guidelines for resuscitation (Supplement).5-7 However, after CPR was performed, the patients and families were informed about the trial.5-7 Informed, written consent from next of kin and unwritten patient consent (whenever feasible) were obtained for stress-dose hydrocortisone in postresuscitation shock.7 The study was approved by the institutional review boards of the participating centers.
We conducted a 3-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Research Randomizer version 4 (Research Randomizer) was used by the study statistician (E.Z.) for group allocation. For each study center, random numbers (range, 1-300) were generated in sets of 4. Each random number of each set was unique and corresponded to 1 of the consecutively enrolled patients. In each set, an odd or even first number resulted in assignment of the corresponding patient to the control or VSE group, respectively. In each study center, the group allocation rule was known solely by the pharmacist, who prepared the study drugs.
Vasopressin and methylprednisolone were prepared in study center pharmacies in identical, preloaded, 5-mL syringes and placed along with epinephrine ampules in boxes bearing patient codes. At the time of patient enrollment, a box was opened and study drugs were injected intravenously according to protocol. Drug injection was followed by 10 mL of normal saline. Confirmation of ROSC at any time point preceding study drug administration resulted in patient exclusion because of “absence of vasopressor-requiring cardiac arrest.”
Resuscitative interventions performed in between 2 consecutive rhythm assessments (ie, CPR cycles) lasted approximately 3 minutes. For the first 5 CPR cycles after enrollment,7 either arginine vasopressin (20 IU/CPR cycle in VSE group; Monarch Pharmaceuticals) or normal saline placebo (control group) were added to epinephrine (1 mg/CPR cycle; Demo). Depending on CPR duration, patients in the VSE group could receive 20 to 100 IU of vasopressin. Furthermore, 40 mg of methylprednisolone sodium succinate (Pfizer) or the corresponding saline placebo was administered solely during the first CPR cycle after enrollment to VSE or control patients, respectively.7 If ROSC was not achieved after the completion of experimental treatment, CPR was continued according to resuscitation guidelines from 2005.7,9 Study drug stability in syringes was confirmed by high-performance liquid chromatography.7 Advanced life support (ALS) was conducted according to contemporary standards.7 Besides administering the experimental drug and recording data, investigators did not participate in ALS.7
At 4 hours after resuscitation, surviving patients in the VSE group with postresuscitation shock received stress-dose hydrocortisone (300 mg/d for ≤7 days and gradual taper; Pfizer).7 Patients with evidence of acute myocardial infarction7 received stress-dose hydrocortisone for 3 days or less to prevent retardation of infarct healing.7,10
Hydrocortisone was available in vials containing 100 mg of hydrocortisone sodium succinate powder. Daily doses were diluted in 100 mL of normal saline at study center pharmacies and administered to patients in the VSE group as continuous infusions. At the time of vasopressor cessation or on day 8 after arrest, daily hydrocortisone was consecutively reduced to 200 mg and 100 mg and then discontinued. Patients in the control group with postresuscitation shock received daily infusions of 100-mL normal saline placebo. Normal saline infusion bags were marked with patient codes. Any prescription of open-label hydrocortisone cancelled the experimental treatment.
Circulatory failure was defined as an inability to maintain mean arterial pressure greater than 70 mm Hg without using vasopressors after volume loading.7,11 Respiratory failure was defined as a ratio of arterial oxygen partial pressure to fraction of inspired oxygen of 200 mm Hg or less.7 Coagulation failure was defined as a platelet count of 50 ×103/μL or less.7 Hepatic failure was defined as a serum bilirubin concentration of 6 mg/dL or greater (to convert bilirubin to μmol/L, multiply by 17.104).7 Renal failure was defined as a serum creatinine level of 3.5 mg/dL or greater, requirement of renal replacement therapy, or both (to convert creatinine to μmol/L, multiply by 88.4).7 Neurologic failure was defined as a Glasgow Coma Scale score of 9 or less.7 Hyperglycemia was defined as a blood glucose level exceeding 200 mg/dL (to convert to mmol/L, multiply by 0.0555).7
Postresuscitation shock was defined as sustained (>4 hours), new postarrest circulatory failure or postarrest need for 50% or greater increase in any prearrest vasopressor/inotropic support targeted to mean arterial pressure greater than 70 mm Hg. Treatment-refractory shock was defined as having a mean arterial pressure less than 70 mm Hg and being unresponsive to norepinephrine infusions of 0.5 μg/kg/min or greater, while central venous pressure, pulmonary artery wedge pressure, or both exceeded 12 mm Hg.
Attempts at CPR were documented according to the Utstein reporting style.7,12 Hemodynamics and gas exchange, electrolytes and glucose, lactate, and administered fluids and vasopressor/inotropic support were determined and recorded during CPR and at approximately 20 minutes and approximately 4 hours after ROSC. Investigational interventions and daily follow-up were conducted by 11 blinded investigators (7 at Evaggelismos and 2 at each collaborating center); current study personnel were not involved in our preliminary RCT.7 At each collaborating center, 3 otherwise study-independent emergency physicians provided assistance with the resuscitation protocol.
Follow-up during days 1 through 10 after randomization included determination and recording of hemodynamics and hemodynamic support, gas exchange, fluid balance of the preceding 24 hours, and peripheral perfusion indices7 at 9 am and daily recording (within 8-9 am) of laboratory data and prescribed medication. We did not measure plasma cytokine concentrations.7 The results of 3 daily determinations (at 8 am, 4 pm, and 12 am) of blood glucose level were also recorded to subsequently analyze the incidence of hyperglycemia. Follow-up to day 60 after arrest included assessment of organ failure and ventilator-free days. Comorbidities and complications throughout ICU/CCU and hospital stay and times to ICU/CCU and hospital discharge were also recorded.
The primary end points were ROSC for 20 minutes or longer (adjusted to Utstein style) and survival to hospital discharge with favorable neurological recovery (ie, Glasgow-Pittsburgh Cerebral Performance Category [CPC]13 score of 1 or 2). The CPC score has 5 categories: good cerebral performance, moderate cerebral disability, severe cerebral disability, coma or vegetative state, and death. A CPC score of 1 means the patient is conscious and able to work/live normally; a CPC score of 2 means the patient is conscious and able to conduct independent daily activities but has disorders such as hemiplegia, seizures, and cognitive changes. Blinded study investigators determined the CPC score by in-person interviews and medical record review.
Secondary end points were arterial pressure during and approximately 20 minutes after CPR; arterial pressure and central venous oxygen saturation (Scvo2) during days 1 through 10 after randomization; number of organ failure–free days during days 1 through 60; and potentially corticosteroid-associated complications such as hyperglycemia, infections, bleeding peptic ulcers, and paresis.7
Based on prior results,7 we predicted rates of survival with favorable neurological recovery of 15% and 4% in the VSE and control groups, respectively. For α = .05 and power = 0.80, a total sample size of 244 patients was required. A target enrollment of 300 patients would compensate for possible drop-outs or incomplete data.
We analyzed data from patients with vasopressor-requiring cardiac arrest according to the intention-to-treat principle; randomized patients who did not require vasopressors were excluded. We tested for heterogeneity (I2 statistic) among study centers with respect to primary end points (Review Manager version 5.0.1; Cochrane Collaboration). Prespecified comparisons included data from patients with postresuscitation shock and from patients who either did or did not require more than 5 mg of epinephrine during CPR. Data are reported as mean (standard deviation), median (interquartile range [IQR]), or number (percentage) unless otherwise specified. Distribution normality was tested by Kolmogorov-Smirnov test. Dichotomous and categorical variables were compared by 2-sided χ2 or Fisher exact test. Continuous variables were compared by 2-tailed, independent samples t test or Mann-Whitney exact U test. P values of multiple t test comparisons conducted between the same subgroups and corresponding to consecutive time points of patient follow-up were multiplied by the number of comparisons (Bonferroni correction); nominal significance level was maintained unchanged.
In patients with postresuscitation shock, we used linear mixed-model analysis to determine the effects of group, time (first 10 days after randomization), group × time interaction, study center, and insulin infusion rate14 (at 8 am of days 1-10) on the daily recordings of mean arterial pressure, Scvo2, arterial blood lactate, vasopressor infusions, fluid balance, hemoglobin concentration, arterial oxygen saturation, and Paco2.7 We adjusted for blood glucose level while testing for dependent variables with a previously documented relationship with blood glucose.15-17 Model goodness-of-fit was assessed using Akaike information criteria and the likelihood ratio test. Fixed-effects significance was determined by F test. Pair-wise comparisons of estimated marginal means were adjusted for multiplicity by Bonferroni correction.
We used multivariable logistic regression to determine odds ratios (ORs) and 95% CIs for effect modifiers for achieving ROSC for 20 minutes or longer and hospital discharge with a CPC score of 1 or 2. For ROSC, the explanatory variables (effect modifiers) included in the model were study center, group,7 cardiac arrest cause,18 either cardiac arrest rhythm18,19 or atropine use19 (as rhythm determined atropine use9), cardiac arrest location,18 weekday (ie, working day or holiday) and time of day,19 and epinephrine19 and bicarbonate dose9 during resuscitation.
For determining the neurologically favorable survival to hospital discharge of the whole study population, we included the same effect modifiers as in ROSC analysis plus the use of therapeutic hypothermia.1,2 In drawing inferences, we included in the models only effect modifiers with a significance level less than .05, obtaining parsimonious models. The final model for ROSC included as explanatory variables the following: group, cardiac rhythm, weekday, time of day, and epinephrine dose. The final model for neurologically favorable survival included as explanatory variables the following: group, cardiac arrest cause, atropine use, epinephrine dose, and hypothermia. Then, for a postresuscitation shock subgroup (n = 149), neurologically favorable survival was predicted using the same explanatory variables as in the whole-population model.
In addition, we used multivariable Cox regression to analyze survival data and determine hazard ratios (HRs) and their 95% CIs for predictors of poor outcome (ie, death or survival with CPC score of ≥3). Statistical significance was set at P < .05. Reported P values are 2-sided, and sample size was calculated by G*Power version 3.1 (Heinrich Heine University). The analysis was performed (by E.Z., A.P., and S.D.M.) using SPSS version 17.0.1 (SPSS); analyses were reviewed by E.Z. Further details about the statistical methods are provided in the online Supplement.
From September 1, 2008, to October 1, 2010, 364 consecutive patients with cardiac arrest were assessed for eligibility. Advanced life support was provided to all patients by resuscitation teams.7 Sixty-four patients were excluded and 300 patients (VSE group, n = 146; control group, n = 154) were enrolled (Figure 1). Another 32 patients (16 in each group) were excluded because ROSC was confirmed during the first postenrollment CPR cycle and before any study drug administration. Excluded patients were not followed up, but survivors’ medical diagnoses at hospital discharge were recorded.7 Discharge diagnoses did not include any neurological disorder in 44 of 96 patients (45.8%).
The data from 268 patients (VSE group, n = 130; control group, n = 138) were analyzed (Figure 1). Heterogeneity among centers was low for ROSC (I2 = 0.16) and neurologically favorable survival (I2 = 0) (eFigures 1 and 2 in the Supplement).
The baseline patient characteristics and cardiac arrest causes are shown in Table 1. Information about cardiac arrest initial rhythms and treatment are shown in Table 2. There was frequent use of atropine and bicarbonate. Short CPR cycle duration resulted in relatively high vasopressor administration rate of approximately 1 dose per 3 minutes (guideline-recommended rate: 1 mg/3-5 minutes).9 Patients in the VSE group had higher probability for ROSC for 20 minutes or longer compared with patients in the control group (109/130 [83.9%] vs 91/138 [65.9%]; OR, 2.98; 95% CI, 1.39-6.40; P = .005) (Figure 1 and eTable 2 in the Supplement). Compared with control patients, VSE patients received less epinephrine during ALS and had shorter ALS duration (Table 2) and higher mean arterial pressure during and after CPR (Table 3).
A periarrest (ie, within 2 hours after ROSC) percutaneous coronary intervention was performed in 7 of 130 patients in the VSE group (5.4%) and 11 of 138 control patients (7.8%; P = .47) (Supplement). Therapeutic hypothermia1,2 was used in 32 of 130 VSE patients (24.6%) and 34 of 138 control patients (24.6%; P > .99) (Supplement). At 4 hours after resuscitation, 76 of 86 surviving VSE patients and 73 of 76 surviving controls had postresuscitation shock and were assigned to receive stress-dose hydrocortisone and saline placebo, respectively (Figure 1). Within 12 hours after arrest, all surviving patients had been admitted to the ICU or CCU.
Full results of multivariable analyses are presented in the online supplement (eResults in the Supplement). Study center had no significant effect on primary outcomes. Compared with patients in the control group, patients in the VSE group had lower hazard of poor outcome during follow-up (HR, 0.70; 95% CI, 0.54-0.92; P = .009) and were more likely to be alive at hospital discharge with favorable neurological recovery (18/130 [13.9%] vs 7/138 [5.1%]; OR, 3.28; 95% CI, 1.17-9.20; P = .02) (Figure 2A). Epinephrine, atropine, and bicarbonate doses during CPR; no use of therapeutic hypothermia; cardiac arrest rhythm (non–ventricular fibrillation/ventricular tachycardia) and cause (noncardiac); and cardiac arrest on a weekend or holiday or during the night (from 11:00 pm to 7:00 am) were associated with increased hazard for poor outcome during follow-up, lower probability of being alive with favorable neurological recovery at hospital discharge, or both. There was no case of brain death declaration after legally specified testing or life support withdrawal.
Among survivors for 4 hours or longer (VSE group, n = 86; control group, n = 76), postarrest morbidity and complications throughout hospital stay and death causes were similar (eTable 25 in the Supplement). Regarding long-term survivors, patients in the VSE group vs control group had comparable mean (SD) ventilator-free days (43.4 days [15.2] vs 39.8 days [19.4]; P = .57), ICU/CCU stays (23.1 days [18.9] vs 29.3 days [23.5]; P = .44), and hospital stays (48.2 days [34.9] vs 59.7 days [39.0]; P = .42). Six patients (3 in each group) had CPC scores of 3 or 4 at hospital discharge.
Among survivors for 4 hours or longer, VSE patients with postresuscitation shock (n = 76) vs corresponding controls (n = 73) had lower hazard of poor outcome during follow-up (HR, 0.61; 95% CI, 0.43-0.89; P = .009) and were more likely to be alive at hospital discharge with favorable neurological recovery (16/76 [21.1%] vs 6/73 [8.2%]; OR, 3.74; 95% CI, 1.20-11.62; P = .02) (Figure 2B).
Full follow-up study-data and violations of the stress-dose hydrocortisone protocol are reported in the online supplement. Compared with controls, patients in the VSE group had significantly more neurologic and renal failure–free days (eFigures 4A and 4B, respectively, in the Supplement) and more ventilator-free days (median, 0 days [IQR, 0-11] vs 0 days [IQR, 0-0]; P = .03).
During days 1 through 10 after randomization, mean arterial pressure and ScvO2 were improved in the VSE group vs the control group (eFigures 5A and 5B, respectively, and 5C and 5D, respectively, in the Supplement). Patients in the VSE group vs control group had a similar frequency of hyperglycemic episodes (confirmed in 94/1269 [7.4%] vs 91/1200 [7.6%] blood glucose determinations; P = .88) but higher numbers of patient-days with insulin treatment aimed at a blood glucose level of 180 mg/dL or less (249/494 patient-days [50.4%] vs 130/361 patient-days [36.0%]; P < .001).
The eResults section in the Supplement outlines post hoc and prespecified subgroup analyses and their main results (eTable 29). Two different subgroups of patients, those treated with hydrocortisone vs those not treated, had favorable HRs for poor outcome. Also, periarrest cerebral perfusion pressure was higher in VSE patients vs controls with intracranial pressure monitoring in place.
In this study of patients with cardiac arrest requiring vasopressors, the combination of vasopressin and epinephrine, along with methylprednisolone during CPR and hydrocortisone in postresuscitation shock, resulted in improved survival to hospital discharge with favorable neurological status, compared with epinephrine and saline placebo. These results are consistent with increased efficacy of the VSE combination vs epinephrine alone during CPR for in-hospital, vasopressor-requiring cardiac arrest.
Recently published results of out-of-hospital cardiac arrest20-23 have cast doubt about epinephrine efficacy, even vs placebo, in achieving long-term survival with favorable neurological recovery. Furthermore, animal data suggest that epinephrine vs placebo,24 vasopressin,25 or combined vasopressin-epinephrine26 reduces microcirculatory cerebral blood flow during CPR.
Cerebral microcirculatory flow is reduced by approximately 60% during chest compression–only CPR and is restored to prearrest levels in 3 minutes or longer after ROSC.27 Periarrest cerebral ischemia depends on CPR duration.27 The present study’s experimental VSE-CPR regimen included methylprednisolone, which may enhance the vasopressor effects of vasopressin28 and epinephrine.29 As periarrest changes in cerebral blood flow may parallel changes in mean arterial pressure,26,27 the improved periarrest hemodynamics and shorter ALS duration of VSE patients vs control patients may reflect attenuated periarrest cerebral ischemia (hypothesis supported by post hoc cerebral perfusion pressure results), possibly contributing to improved neurological recovery.
The improved early postarrest mean arterial pressure and Scvo2, lower CPR dose of epinephrine,30,31 shorter ALS duration, and use of methylprednisolone during CPR32 are consistent with improved postarrest cardiac performance,30-32 possibly leading to better outcomes for patients in the VSE group.31 Atropine and bicarbonate use during CPR may have contributed to poor patient outcomes in both groups (eTables 4 and 7 in the Supplement).
Our study protocol precluded assessment of the effects of hydrocortisone7,33 because of the possible additional benefit of vasopressin34 or steroid35 use during CPR. The half life of vasopressin is 24 minutes,36 and methylprednisolone may start acting within 60 minutes.37 In the present study, methylprednisolone may have potentiated the periarrest, pressor effects of vasopressin.
There are no published data showing that postarrest glucocorticoid administration is neuroprotective.33 Results of post hoc and sensitivity analyses support the hypothesis that postarrest hydrocortisone may be associated with reduced hazard of poor outcome (eTable 29 in the Supplement). However, this hypothesis requires further evaluation in RCTs.
Additional limitations include lack of determination of prevasopressor CPR hemodynamics, baseline stress hormone concentrations,7 physiological variables at multiple post-ROSC time points, and postarrest myocardial function.31 In addition, the prespecified, limited sample size did not enable reliable assessment of 1-year outcomes.
Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status.
Corresponding Author: Spyros D. Mentzelopoulos, MD, Department of Intensive Care Medicine, Evaggelismos General Hospital, 45-47 Ipsilandou St, Athens 10675, Greece (email@example.com).
Author Contributions: Dr Mentzelopoulos had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Mentzelopoulos, S. G. Zakynthinos.
Acquisition of data: Malachias, Chamos, Konstantopoulos, Ntaidou, Kolliantzaki, Theodoridi, Ischaki, Makris, E. Zakynthinos, Sourlas, Aloizos.
Analysis and interpretation of data: Mentzelopoulos, Malachias, Papastylianou, Zintzaras, S. G. Zakynthinos.
Drafting of the manuscript: Mentzelopoulos.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Mentzelopoulos, Papastylianou, Zintzaras.
Obtained funding: Mentzelopoulos, S. G. Zakynthinos.
Administrative, technical, or material support: Mentzelopoulos, S. G. Zakynthinos.
Study supervision: Mentzelopoulos, E. Zakynthinos, Sourlas, S. G. Zakynthinos.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: This work has been funded in part by the Greek Society of Intensive Care Medicine and the Project “Synergasia” (ie, Cooperation) of the Greek Ministry of Education (09ΣYN-12-1075). All funding was used for purchasing necessary materials for the study (eg, study drugs, study drug boxes, syringes) and for partial coverage of expenses related to a scientific congress presentation.
Role of the Sponsor: The funding bodies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Study Personnel:Chairpersons: Spyros D. Mentzelopoulos (principal investigator); Spyros G. Zakynthinos (study director and chair). Statistician: Elias Zintzaras, MD, PhD. Pharmacists: John Portolos, PhD (Evaggelismos General Hospital), Irini Pneumatikaki (Larissa University Hospital), George Ganiatsos (401 Greek Army Hospital). Independent Main End Point and Safety Monitoring Committee: Panagiotis Politis, MD; Marinos Pitaridis, MD (Evaggelismos General Hospital); Zoi Daniil, MD, PhD (Larissa University Hospital); Stavros Gourgiotis, MD (401 Greek Army Hospital). Quality Assurance and Data Management: Panagiotis Politis, Marinos Pitaridis, Zoi Daniil, Stavros Gourgiotis, John Portolos, Irini Pneumatikaki, George Ganiatsos. Assistance With the CPR Protocols: Eleftherios Chouliaras, MD; Christos Nastoulis, MD; George Antiochos, MD (401 Greek Army Hospital); Paris Zygoulis, MD; Georgia Ganelli, MD; Katerina Koursothimiou, MD (Larissa University Hospital).
Previous Presentations: This work was presented in part at the 24th Annual Congress of the European Society of Intensive Care Medicine, Berlin, Germany, October 1-5, 2011. Dr Mentzelopoulos gave invited lectures on the “Potential Contribution of Corticosteroids to Positive Cardiac Arrest Outcomes” at the Weil Conference on Cardiac Arrest, Shock, and Trauma; Milan, Italy; September 8-9, 2012; and the 2012 Resuscitation Science Symposium; Los Angeles, California; November 3-4, 2012.
Correction: This article was corrected online September 26, 2013, for errors in the byline and reference citations.